New research highlights postnatal regeneration limits and pathological remodeling of the cardiac conduction system after myocardial infarction, uncovering mechanisms behind clinical arrhythmogenesis ...

When patients with congenital heart issues have an operation, surgeons have to proceed with an "eye of faith" as they work around conduction tissue—a network of cells and electrical signals that ...

NEW ORLEANS -- Among patients with heart failure, conduction system pacing-guided cardiac resynchronization therapy was associated with improvements in left ventricular ejection fraction (LVEF) ...

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...

Researchers have produced the most detailed and comprehensive human Heart Cell Atlas to date, including the specialized tissue of the cardiac conduction system -- where the heartbeat originates. In a ...

New research in Sweden has produced a "blueprint" revealing how the human heart is built during prenatal development. It offers insights that could lead to improved prenatal care and new treatments ...

Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...

Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...

The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...